More than half of FDA trials recruit from lower middle income countries, but country enrollment is rarely reported

Corporate businessmen working on tablet at office

An analysis of 144 pivotal trials for U.S. Food and Drug Administration (FDA)-approved medications in cancer, cardiovascular disease, and neurology has found that more than half of the studies recruit patients from low- and middle-income countries (LMIC). However, available country data for trials are sparse, contributing to problems with both study verification and participant recruitment ethics. The analysis is published in Annals of Internal Medicine.

Over half of Mississippi’s rural hospitals risk closing

Previous article

More Republicans died than Democrats after COVID vaccines came out

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations